We have located links that may give you full text access.
1D.10: PREDICTORS AND OUTCOMES OF CONTRAST-INDUCED ACUTE KIDNEY INJURY IN PATIENTS WITH PRIMARY PERCUTANEOUS INTERVENTION.
Journal of Hypertension 2015 June
OBJECTIVE: The incidence of contrast-induced acute kidney injury (CI-AKI) is rising due to increased use of coronary angiography and percutaneous coronary intervention (PCI). Patients undergoing primary PCI are at high risk of CI-AKI, a complication that negatively affects outcomes. The aim of the study was to evaluate the incidence, predictors and outcomes of CI-AKI in patients with ST-segment elevation myocardial infarction (STEMI) and primary PCI.
DESIGN AND METHOD: 216 patients with STEMI and primary PCI (143 male, 64 ± 13 years (M ± SD), arterial hypertension 90%, previous myocardial infarction 27%, diabetes mellitus 21%, known chronic kidney disease 7%, anemia 14%, heart failure 62%, left ventricular ejection fraction (LV EF) 44 ± 15%) were examined. CI-AKI was defined using 2012 KDIGO Guidelines. Mann-Whitney test was performed. P < 0.05 was considered statistically significant.
RESULTS: 20% of patients developed CI-AKI. Stages 1 and 2 of CI-AKI were found in 77 and 33% of cases accordingly. CI-AKI developed in 66% of cases in first 48 hours after PCI. Patients with versus without CI-AKI were older (69 ± 13 vs 63 ± 12 years, p < 0.05), had higher baseline serum creatinine (104 ± 31 vs 87 ± 22 μmol/l, p < 0.001), lower LV EF (37 ± 10 vs 41 ± 14%, p < 0.05), higher rate of CKD (21 vs 3.5%, p < 0.001) and higher rate of therapy with nephrotoxic antibiotics (19 vs 3.5%, p < 0.05), loop diuretics (72 vs 39%, p < 0.05), mineralocorticoid receptor antagonists (56 vs 37%, p < 0.05), higher contrast volume (CV) (282 ± 94 vs 236 ± 85 ml, p < 0.05), contrast media volume/estimated glomerular filtration rate ratio (CV/eGFR) (4,02 ± 2,15 vs 2,32 ± 1,08, p < 0.05), higher rate of multivessel coronary damage (84 vs 59%, p < 0.05). Patients with CI-AKI had higher risk of 30-days mortality (10 vs 3%, p < 0.05) and similar rate of 6 months rehospitalizations (66 vs 46%, p > 0.05).
CONCLUSIONS: CI-AKI in patients with STEMI and primary PCI developed in 20% of cases, predominantly in first 48 hours after PCI. CI-AKI was associated with higher rate of CKD, therapy with nephrotoxic drugs, multivessel coronary damage, higher baseline serum creatinine, CV/eGFR. CI-AKI had negative impact on 30-days mortality.
DESIGN AND METHOD: 216 patients with STEMI and primary PCI (143 male, 64 ± 13 years (M ± SD), arterial hypertension 90%, previous myocardial infarction 27%, diabetes mellitus 21%, known chronic kidney disease 7%, anemia 14%, heart failure 62%, left ventricular ejection fraction (LV EF) 44 ± 15%) were examined. CI-AKI was defined using 2012 KDIGO Guidelines. Mann-Whitney test was performed. P < 0.05 was considered statistically significant.
RESULTS: 20% of patients developed CI-AKI. Stages 1 and 2 of CI-AKI were found in 77 and 33% of cases accordingly. CI-AKI developed in 66% of cases in first 48 hours after PCI. Patients with versus without CI-AKI were older (69 ± 13 vs 63 ± 12 years, p < 0.05), had higher baseline serum creatinine (104 ± 31 vs 87 ± 22 μmol/l, p < 0.001), lower LV EF (37 ± 10 vs 41 ± 14%, p < 0.05), higher rate of CKD (21 vs 3.5%, p < 0.001) and higher rate of therapy with nephrotoxic antibiotics (19 vs 3.5%, p < 0.05), loop diuretics (72 vs 39%, p < 0.05), mineralocorticoid receptor antagonists (56 vs 37%, p < 0.05), higher contrast volume (CV) (282 ± 94 vs 236 ± 85 ml, p < 0.05), contrast media volume/estimated glomerular filtration rate ratio (CV/eGFR) (4,02 ± 2,15 vs 2,32 ± 1,08, p < 0.05), higher rate of multivessel coronary damage (84 vs 59%, p < 0.05). Patients with CI-AKI had higher risk of 30-days mortality (10 vs 3%, p < 0.05) and similar rate of 6 months rehospitalizations (66 vs 46%, p > 0.05).
CONCLUSIONS: CI-AKI in patients with STEMI and primary PCI developed in 20% of cases, predominantly in first 48 hours after PCI. CI-AKI was associated with higher rate of CKD, therapy with nephrotoxic drugs, multivessel coronary damage, higher baseline serum creatinine, CV/eGFR. CI-AKI had negative impact on 30-days mortality.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app